Skip to main content Accessibility help
×
Home

Imaging biomarkers for amyloid: a new generation of probes and what lies ahead

  • Antoine Leuzy (a1) (a2), Eduardo Rigon Zimmer (a1) (a2) (a3), Venkat Bhat (a4), Pedro Rosa-Neto (a1) (a2) and Serge Gauthier (a2)...

Extract

Since the original 1984 criteria for Alzheimer's disease (AD), put forth by a work group jointly established by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) (McKhann et al., 1984), important advances have occurred in our ability to detect AD pathophysiology, with the incorporation of biomarkers – defined as anatomic, biochemical, or physiologic parameters that provide in vivo evidence of AD neuropathology (Cummings, 2011) – that can improve the certainty of AD diagnosis. Use of imaging biomarkers such as positron emission tomography (PET) with amyloid ligands, particularly in asymptomatic and pre-dementia stages of AD, however, has been the subject of debate (Dubois et al., 2013), with arguments both for and against the biomarker driven diagnosis of AD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Imaging biomarkers for amyloid: a new generation of probes and what lies ahead
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Imaging biomarkers for amyloid: a new generation of probes and what lies ahead
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Imaging biomarkers for amyloid: a new generation of probes and what lies ahead
      Available formats
      ×

Copyright

References

Hide All
Clark, C. M. et al. (2012). Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurology, 11, 669678. doi:10.1016/S1474-4422(12)70142-4.
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E. and Ikonomovic, M. D. (2012). Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Advances in Pharmacology, 64, 2781. doi:10.1016/B978-0-12-394816-8.00002-7.
Cselenyi, Z. et al. (2012). Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. Journal of Nuclear Medicine, 53, 415424. doi:10.2967/jnumed.111.094029.
Cummings, J. L. (2011). Biomarkers in Alzheimer's disease drug development. Alzheimer's & Dementia, 7, e1344. doi:10.1016/j.jalz.2010.06.004.
Dubois, B. and Albert, M. L. (2004). Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurology, 3, 246248. doi: 10.1016/S1474-4422(04)00710-0.
Dubois, B. et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734746. doi:10.1016/S1474-4422(07)70178-3.
Dubois, B., Gauthier, S. and Cummings, J. (2013). The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics, 25, 175177. doi:10.1017/S1041610212002098.
Fodero-Tavoletti, M. T. et al. (2007). In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. The Journal of Neuroscience, 27, 1036510371. doi:10.1523/JNEUROSCI.0630-07.2007.
Gauthier, S. and Rosa-Neto, P. (2013). Dementia: disclosure of results to participants in dementia research. Nature Reviews Neurology, 9, 608609. doi:10.1038/nrneurol.2013.213.
Ikonomovic, M. D. et al. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 131, 16301645. doi:10.1093/brain/awn016.
Johnson, K. A. et al. (2013a). Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's & Dementia, 9, e-116. doi:10.1016/j.jalz.2013.01.002.
Johnson, K. A. et al. (2013b). Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Journal of Nuclear Medicine, 54, 10111013. doi:10.2967/jnumed.113.127068.
Jureus, A. et al. (2010). Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. Journal of Neurochemistry, 114, 784794. doi:10.1111/j.1471-4159.2010.06812.x.
Karlawish, J. (2011). Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology, 77, 14871493. doi:10.1212/WNL.0b013e318232ac1a.
Klunk, W. E. et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306319. doi:10.1002/ana.20009.
Lockhart, A. et al. (2007). PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain, 130, 26072615. doi:10.1093/brain/awm191.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939944.
Mintun, M. A. et al. (2006). [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology, 67, 446452. doi:10.1212/01.wnl.0000228230.26044.a4.
Ng, S. Y., Villemagne, V. L., Masters, C. L. and Rowe, C. C. (2007). Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Archives of Neurology, 64, 11401144. doi:10.1001/archneur.64.8.1140.
Price, J. C. et al. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow & Metabolism, 25, 15281547. doi:10.1038/sj.jcbfm.9600146.
Rabinovici, G. D. et al. (2007). 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 68, 12051212. doi:10.1212/01.wnl.0000259035.98480.ed.
Rowe, C. C. and Villemagne, V. L. (2011). Brain amyloid imaging. Journal of Nuclear Medicine, 52, 17331740. doi:10.2967/jnumed.110.076315.
Rowe, C. C. and Villemagne, V. L. (2013). Brain amyloid imaging. Journal of Nuclear Medicine Technology, 41, 1118. doi:10.2967/jnumed.110.076315.
Rowe, C. C. et al. (2007). Imaging beta-amyloid burden in aging and dementia. Neurology, 68, 17181725. doi:10.1212/01.wnl.0000261919.22630.ea.
Rowe, C. C. et al. (2008). Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94–9172, a novel PET tracer: proof of mechanism. Lancet Neurology, 7, 129135. doi: 10.1016/S1474-4422(08)70001-2.
Rowe, C. C. et al. (2013). Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. Journal of Nuclear Medicine, 54, 880886. doi:10.2967/jnumed.112.114785.
Shalowitz, D. I. and Miller, F. G. (2008). Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Medicine, 5, e91. doi:10.1371/journal.pmed.0050091.
Shulman, M. B., Harkins, K., Green, R. C. and Karlawish, J. (2013). Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology, 81, 11141121. doi:10.1212/WNL.0b013e3182a55f4a.
Sperling, R. A. et al. (2011a). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7, 280292. doi:10.1016/j.jalz.2011.03.003.
Sperling, R. A., Jack, C. R., Jr. and Aisen, P. S. (2011b). Testing the right target and right drug at the right stage. Science Translational Medicine, 3, 111cm133. doi:10.1126/scitranslmed.3002609.
Vallabhajosula, S. (2011). Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Seminars in Nuclear Medicine, 41, 283299. doi:10.1053/j.semnuclmed.2011.02.005.
Vandenberghe, R. et al. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology, 68, 319329. doi:10.1002/ana.22068.
Villemagne, V. L. et al. (2012). Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 39, 983989. doi:10.1007/s00259-012-2088-x.
Wolk, D. A. et al. (2011). Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Archives of Neurology, 68, 13981403. doi:10.1001/archneurol.2011.153.
Wu, L., Rosa-Neto, P. and Gauthier, S. (2011). Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Molecular Diagnosis & Therapy, 15, 313325. doi:10.2165/11595090-000000000-00000.
Zimmer, E. et al. (2013). [18F]NAV4694 shows higher binding and wider dynamic range compared with [11C]PiB in Alzheimer's disease postmortem tissue. Alzheimer's & Dementia, 9, P2223. doi:10.1016/j.jalz.2013.05.1161.

Imaging biomarkers for amyloid: a new generation of probes and what lies ahead

  • Antoine Leuzy (a1) (a2), Eduardo Rigon Zimmer (a1) (a2) (a3), Venkat Bhat (a4), Pedro Rosa-Neto (a1) (a2) and Serge Gauthier (a2)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.